UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 24, 2015

 

 

MEDBOX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   000-54928   45-3992444

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

600 Wilshire Blvd. Ste. 1500

Los Angeles, CA 90017

(Address of principal executive offices) (zip code)

(800)-762-1452

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

Jennifer Love Resignation

On September 24, 2015, Jennifer Love resigned from her positions as a member of the board of directors (the “Board”) of Medbox, Inc. (the “Company”), chairperson of the Company’s audit committee and a member of its special committee, effective immediately. Ms. Love confirmed that she resigned because of time constraints and new professional obligations and not because of any disagreement with the Company. The Company has initiated a search for a successor to serve on its Board. On September 28, 2015, the Company also appointed current director Ambassador Ned L. Siegel as interim chairperson of its audit committee.

A copy of the press release issued by the Company announcing Ms. Love’s resignation is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number		    Description
99.1    Press Release dated September 29, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDBOX, INC.
Dated: September 29, 2015     By:  

/s/ C. Douglas Mitchell

    Name:   C. Douglas Mitchell
    Title:   Chief Financial Officer

EXHIBIT INDEX

 

Exhibit
Number		    Description
99.1    Press Release dated September 29, 2015.


Exhibit 99.1

 

LOGO

Jennifer Love Relinquishes Medbox Board Post

To Accept New Full-Time Executive Position at Another Company

- Medbox Initiates Search for Successor -

(Los Angeles, CA, September 29, 2015) — Medbox, Inc. (OTCQB: MDBX), a provider of specialized services to the cannabis sector, including operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved, today announced that Jennifer Love is relinquishing her post as a member of the company’s Board of Directors because of time constraints and new professional obligations as a result of her relocation.

Medbox said it has initiated a search for a successor to serve on its board.

“We wish Jennifer all the best in her new endeavor and extend appreciation for her many contributions to Medbox during the company’s successful transformation,” said Ambassador Ned L. Siegel, Medbox Chairman of the Board.

“My time on the board has been an incredible experience,” said Love. “I am gratified that today’s Medbox is in great hands and on a positive trajectory.”

Current directors of Medbox include Ambassador Siegel, who has been appointed interim Chairman of the Audit Committee, and J. Mitchell Lowe, co-founder of Netflix and former Redbox President.

About Medbox, Inc.

Medbox, Inc., a leader in the rapidly emerging cannabis sector, provides specialized services to operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved. Through trusted clients and affiliates, the company promotes efficient, consistent, high quality products that are priced right, readily available and safely packaged. For more information about the company or to explore partnership, please visit www.medbox.com.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements, including, but not limited to, filling the the vacancy on the company’s board, are based on current beliefs and expectations and are inherently subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the company’s control. In addition, certain forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties also include, but are not limited to, regulatory developments in the industry, as well as political and economic conditions present within the industry. For a more detailed description of the risk factors associated with the company, please refer to the company’s latest Annual Report on Form 10-K, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. The company does not assume any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made, unless required by law.

For more information, contact:

Janet Simmons

PondelWilkinson Inc.

310-279-5980

pwinvestor@pondel.com